ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial

Study limitation reported by the research below: “No histologic endpoints (e.g., NAS score, fibrosis regression) were assessed; liver fat by MRI-PDFF is a surrogate only.”